Test Price
550 AED✅ Home Collection Available
FMF First Trimester Screening Test in UAE | 550 AED | DNA Labs UAE
Executive Summary & Core Metrics
Our FMF First Trimester Screening Test provides early risk assessment for Trisomy 21 (Down syndrome), Trisomy 18, and Trisomy 13 between 11–13 weeks of pregnancy. It combines maternal serum biomarkers (free β-hCG and PAPP-A) with high-resolution ultrasound nuchal translucency (NT) measurement, processed through FMF-certified risk algorithm at our ISO 9001:2015 accredited laboratory.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation by our genetics team.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The FMF First Trimester Screening is a non-invasive prenatal test that evaluates the risk of common chromosomal abnormalities using a combination of biochemical markers and ultrasound findings. It is recommended for all pregnant women in the UAE between 11 and 13 weeks 6 days of gestation.
| Feature | Our Test (FMF Combined First Trimester Screening) | Closest Alternative (NIPT/cfDNA) |
|---|---|---|
| Methodology | Electrochemiluminescence Immunoassay (ECLIA) for PAPP-A, free β-hCG + NT ultrasound; FMF-certified algorithm | Next-Generation Sequencing (NGS) of cell-free fetal DNA |
| Precision (T21 Detection) | ~90–95% detection rate at 5% false-positive rate | >99% detection rate, very low false-positive rate |
| Turnaround Time | Same-day report once ultrasound data is submitted | 5–7 working days |
| Cost | 550 AED | Significantly higher (typically 1200–2500 AED) |
| Ultrasound Mandatory | Yes (CRL 45–84 mm, NT, nasal bone assessment) | Optional but recommended |
Physician Insight & Safety Protocols
“As a Consultant Medical Genetics, I emphasize that the FMF First Trimester Screening is a highly effective risk assessment tool for common chromosomal aneuploidies like Trisomy 21, 18, and 13. While it provides invaluable early insights, it is crucial to understand it remains a screening test. Confirmatory diagnostic procedures such as CVS or amniocentesis are indicated for screen-positive results. Our team is dedicated to providing thorough pre- and post-test counseling to ensure informed decision-making throughout your prenatal journey.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Clinical Advisory & Exclusion Criteria
Advisory Notice
Do not discontinue prescribed medication without consulting your referring physician. The FMF screen is a risk assessment, not a diagnostic test.
Exclusion Criteria
- Gestational age beyond 13 weeks 6 days
- Multiple pregnancy with more than 2 fetuses
- Maternal weight exceeding 120 kg
- Known chromosomal anomaly in current pregnancy
- Incomplete ultrasound data (CRL, NT, nasal bone)
Patient FAQ & Clinical Guidance
1. What does the FMF First Trimester Screening test for?
It screens for the risk of Trisomy 21 (Down syndrome), Trisomy 18 (Edwards syndrome), and Trisomy 13 (Patau syndrome) by analyzing maternal serum biomarkers and nuchal translucency (NT) ultrasound measurements.
2. When should I have this test?
The test window is strictly between 11 weeks and 13 weeks 6 days of gestation. Accurate crown-rump length (CRL) and NT measurement are essential during this period.
3. How reliable is the FMF first trimester screen?
The combined test has a detection rate of approximately 90-95% for Trisomy 21, with a 5% false-positive rate. It is the most effective non-invasive screening tool within its gestational window.
4. What pre-test information is required?
Accurate maternal demographics, LMP, diabetic status, weight, IVF history, smoking status, and a recent ultrasound report (CRL, NT, nasal bone) are mandatory for the risk algorithm. Fasting is not required.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance & Data Protection
DNA Labs UAE strictly adheres to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All clinical testing, patient consent, and safety protocols are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability. Our DHA-licensed facility (License No. 1143) ensures that all prenatal screening data is processed, stored, and transmitted with the highest standards of confidentiality and information security. Laboratory operations are ISO 9001:2015 certified, reinforcing our commitment to quality and regulatory excellence in the UAE healthcare sector.
Clinical & Logistical Metadata
| Test Name | FMF First Trimester Screening |
| Price (AED) | 550 |
| Turnaround Time | Same-day report once ultrasound data is submitted |
| Sample Type / Matrix | Maternal Serum (SST Tube) + Ultrasound NT Data |
| Methodology Used | Electrochemiluminescence Immunoassay (ECLIA) + FMF-Certified Risk Algorithm |
| ICD-10-CM Code | Z36.0, Z13.71, Z36.89 |
| LOINC Code | 49091-2 |
| DHA Facility License & Lab Address | DHA License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians